Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDC00201

Target Information
NameMitogen-activated protein kinase 14    
Type of targetClinical trial target    
CSAID binding protein    
Cytokine suppressive anti-inflammatory drug binding protein    
MAP kinase MXI2    
MAP kinase p38    
MAP kinase p38alpha    
MAX-interacting protein 2    
Mitogen-activated protein kinase p38    
Mitogen-activated protein kinase p38 alpha    
P38 Mitogen-activated protein kinase alpha    
P38 mitogen activated protein kinase    
DiseaseAdult respiratory distress syndrome
[ICD9: 518.5, 518.82   ICD10: J80]
Alzheimer's disease
[ICD9: 331.0   ICD10: G30]
Crescentic glomerulonephritis
[ICD9: 580-582   ICD10: N00, N01, N03, N18]
Crohn's disease, unspecified
[ICD9: 555   ICD10: K50]
Cytokine-mediated diseases[5]
Insulin resistance[9]
Multiple myeloma
[ICD9: 203.0   ICD10: C90.0]
[ICD9: 696   ICD10: L40]
Rheumatoid arthritis, unspecified
[ICD9: 710-719, 714   ICD10: M00-M25, M05-M06]
Skin diseases[12]
[ICD9: 437.6, 453, 671.5, 671.9   ICD10: I80-I82]
Drug(s)LosmapimodPhase IICardiovascular disease, COPD and depression[13]
DilmapimodPhase IAcute lung injury & acute respiratory distress syndrome[13]
GSK610677Phase ICOPD[13]
BioChemical ClassTransferases transferring phosphorus-containing groups    
EC NumberEC
PathwayAmyotrophic lateral sclerosis (ALS)
Epithelial cell signaling in Helicobacter pylori
Fc epsilon RI signaling pathway
GnRH signaling pathway
Leukocyte transendothelial migration
MAPK signaling pathway
T cell receptor signaling pathway
Toll-like receptor signaling pathway
VEGF signaling pathway
UniProt IDQ16539
PDB Structure1A9U; 1DI9; 1M7Q; 1OZ1; 1W82; 1WBO; 1WBW; 1ZZ2.    
FunctionResponds to activation by environmental stress, pro- inflammatory cytokines and lipopolysaccharide (lps) by phosphorylating a number of transcription factors, such as elk-1 and atf2 and several downstream kinases, such as mapkapk2 and mapkapk5.    
Related US Patent6,541,477
Target ValidationClick to Find Target Validation Information.    
Inhibitor (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone[14]
3- (Benzyloxy)Pyridin-2-Amine[15]
4- (2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine[18]
4-[ (3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol[20]
6- (4-Fluoro-phenylsulfanyl)-9H-purine[19]
9- (4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine[19]
9-Benzyl-6- (4-fluoro-phenylsulfanyl)-9H-purine[19]
CI-1040,   PD-18435,   PD-184352[23]
Inhibitor of P38 Kinase[15]
N- (3-[32]
N- (3-[32]
N- (4-[32]
N- (4-fluorobenzyl)-N-[33]
N- (4-methyl-benzyl)-4-phenoxy-benzamide[32]
PD-0166326,   PD-166326[35]
Phenyl- (3-phenyl-1H-indazol-6-yl)-amine[36]
Pyridinyl imidazole compounds[7]
SB 202190[6]
SB 203580[8][39]
SB 235699[7]
SK&F-86002,   SK-86002[30]
Vertex 745 (VX745)[7]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1p38 mitogen-activated protein kinase inhibition attenuates intercellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells. Surgery. 1998 Aug;124(2):403-7; discussion 408. To Reference
Ref 2p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. J Mol Neurosci. 2002 Dec;19(3):295-9. To Reference
Ref 3Involvement of p38 mitogen-activated protein kinase followed by chemokine expression in crescentic glomerulonephritis. Am J Kidney Dis. 2001 Dec;38(6):1169-77. To Reference
Ref 4From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn's disease. Ann N Y Acad Sci. 2002 Nov;973:349-58. To Reference
Ref 5Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem. 1999 Sep;6(9):807-23. To Reference
Ref 6Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res. 2003 Oct 1;59(4):893-900. To Reference
Ref 7Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. To Reference
Ref 8The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 2001 Aug 1;98(3):667-73. To Reference
Ref 9Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J Exp Biol. 2002 Dec;205(Pt 23):3739-46. To Reference
Ref 10Blood. 2003 Jan 15;101(2):703-5. Epub 2002 Sep 5.Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. To Reference
Ref 11Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003 Sep;48(9):2670-81. To Reference
Ref 12High efficiency of 5-aminolevulinate-photodynamic treatment using UVA irradiation. Carcinogenesis. 2001 Jun;22(6):879-83. To Reference
Ref 13GSK. Product Development Pipeline. February 2009. To Reference
Ref 14J Med Chem. 2006 Mar 9;49(5):1562-75.Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. To Reference
Ref 15Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 16Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. To Reference
Ref 17J Med Chem. 2004 Dec 2;47(25):6239-47.Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. To Reference
Ref 18J Med Chem. 2005 Sep 22;48(19):5966-79.Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. To Reference
Ref 19J Med Chem. 2005 Feb 10;48(3):710-22.Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. To Reference
Ref 20J Med Chem. 2006 Nov 2;49(22):6500-9.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. To Reference
Ref 21J Med Chem. 2006 Sep 21;49(19):5671-86.Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. To Reference
Ref 22Bioorg Med Chem. 2010 Aug 1;18(15):5738-48. Epub 2010 Jun 4.The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. To Reference
Ref 23Biochem J. 2000 Oct 1;351(Pt 1):95-105.Specificity and mechanism of action of some commonly used protein kinase inhibitors. To Reference
Ref 24Bioorg Med Chem Lett. 2008 Mar 15;18(6):1762-7. Epub 2008 Feb 16.The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. To Reference
Ref 25Bioorg Med Chem Lett. 2006 Aug 15;16(16):4339-44. Epub 2006 Jun 12.Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development. To Reference
Ref 26Bioorg Med Chem. 2010 Mar 15;18(6):2204-18. Epub 2010 Feb 8.In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. To Reference
Ref 27J Med Chem. 2006 Apr 6;49(7):2210-21.Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. To Reference
Ref 28Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10. Epub 2008 Jun 6.Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. To Reference
Ref 29Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. Epub 2005 Nov 2.The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. To Reference
Ref 30J Med Chem. 2002 Jun 20;45(13):2733-40.From imidazoles to pyrimidines: new inhibitors of cytokine release. To Reference
Ref 31J Med Chem. 2003 Jul 17;46(15):3230-44.Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. To Reference
Ref 32Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9. Epub 2005 Sep 19.Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. To Reference
Ref 33Bioorg Med Chem Lett. 2010 Apr 15;20(8):2560-3. Epub 2010 Mar 2.Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides. To Reference
Ref 34J Med Chem. 2010 Mar 25;53(6):2345-53.Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. To Reference
Ref 35Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. Epub 2009 Oct 23.Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. To Reference
Ref 36Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9.Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. To Reference
Ref 37Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.Imidazopyrimidines, potent inhibitors of p38 MAP kinase. To Reference
Ref 38Bioorg Med Chem Lett. 2008 Jul 1;18(13):3745-8. Epub 2008 May 16.Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells. To Reference
Ref 39Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference
Ref 40Bioorg Med Chem Lett. 2005 Nov 1;15(21):4666-70.The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. To Reference
Ref 41Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7. Epub 2008 Jun 12.Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. To Reference
Ref 42Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94.Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. To Reference
Ref 43J Med Chem. 2003 Dec 18;46(26):5651-62.Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. To Reference
Ref 44Bioorg Med Chem Lett. 2004 Nov 1;14(21):5383-7.A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543